Compare KWR & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | PHVS |
|---|---|---|
| Founded | 1918 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 1994 | 2020 |
| Metric | KWR | PHVS |
|---|---|---|
| Price | $155.66 | $31.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $193.14 | $57.58 |
| AVG Volume (30 Days) | 98.2K | ★ 624.5K |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $1,888,634,000.00 | N/A |
| Revenue This Year | $7.73 | N/A |
| Revenue Next Year | $4.53 | N/A |
| P/E Ratio | $58.41 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $112.18 | $21.02 |
| 52 Week High | $183.01 | $43.25 |
| Indicator | KWR | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 48.58 |
| Support Level | $153.07 | $27.80 |
| Resistance Level | $163.12 | $31.49 |
| Average True Range (ATR) | 3.58 | 1.40 |
| MACD | -0.18 | 0.25 |
| Stochastic Oscillator | 35.45 | 81.70 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.